Phase 3 Start

IPIX: Phase3_Start: An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement

Name: Phase3_Start: An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement
Start: 2027-01-01
End: 2027-01-01

January 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2027
Company: Innovation Pharmaceuticals Inc. (IPIX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement

January 1, 2027

IPIX overview →

Company: Innovation Pharmaceuticals Inc. (IPIX)